BCL2 and plasma cell myeloma: Lastly, drugs that inhibit or decrease the expression of the anti-apoptotic protein Bcl-2 are well tolerated and induce substantial responses when used as a monotherapy or combined with dexamethasone in chronic lymphocytic leukemia or multiple myeloma (101, 102) or combined with azacytidine, decitabine or low-dose cytarabine in acute myeloid leukemia (99), the latter receiving FDA approval.